November 2009
M T W T F S S
« Sep   Mar »
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Recent Posts

Random Posts

Prescription AIDS Drugs

Contact Us

Please remember that all posts are submitted by users. We enrich the content of the post by dynamically adding URL's to mentioned websites. If you wish to remove your organization's link from one of the posts, please contact us at webmaster@discussaids.com

Two Yale School of Medicine physicians have been awarded a $4.1 million research grant from the National Institutes of Health (NIH) to study a new pharmacological treatment for newly released HIV-positive inmates with alcohol dependence who are transitioning back into the community.

The U.S. prison population is disproportionately impacted by HIV and by alcohol and drug abuse. A majority of HIV-positive inmates also have substance abuse disorders. Though many are treated successfully for both HIV and substance abuse while incarcerated, they face enormous challenges when released.

“Released HIV-positive inmates who relapse to alcohol and drug use are less likely to adhere to HIV treatment, including antiretroviral drugs, and more likely to engage in high-risk behavior,” according to Frederick L. Altice, M.D., professor at Yale School of Medicine, director of clinical and community research at the Yale AIDS Program and one of the two principal investigators.

The prestigious NIH grant is the first of its stature for Sandra Springer, M.D., assistant professor of medicine and co-principal investigator - a junior investigator whose career has already benefited from a career development award from the NIH. In the clinical trial led by Springer and Altice, 125 HIV-positive prisoners with alcohol dependence who are transitioning back into society will receive subcutaneous (depot) injections of naltrexone. Though the medication has been previously shown to benefit those with alcohol dependence, HIV-infected individuals were never previously included in clinical trials.

All subjects in the trial, whether getting naltrexone or the placebo, will receive comprehensive case-management services and 24 weeks of counseling. “This is the first time that depot naltrexone will be formally tested in HIV-infected patients,” says Springer. She adds, “We hope to learn whether a medication known to benefit those with alcohol problems will also help assist with HIV treatment and prevent a relapse to high-risk behaviors. Our study could confirm that treating one disease, alcohol dependence, can actually fight two life-threatening conditions.”

Source
Yale University

View drug information on Naltrexone Hydrochloride Tablets.

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google

Related posts:

  1. Video Game To Help Urban Teens Avoid HIV Infection Focus Of Nearly $4 Million Grant To Yale Creating a video game to help teens avoid sex, drugs...
  2. Yale And University Of Malaya Join Forces To Battle HIV In Prisons In the hope of stemming one of the biggest...
  3. Program Once Reserved For Alabama Inmates With HIV/AIDS Expanded To All Inmates Patient / Public: Health Professional: Article Opinions:  ...
  4. More Than Four Million HIV-positive People Now Receiving Life-saving Treatment More than 4 million people in low- and middle-income countries...
  5. Outstanding Minority Physicians Receive Awards Dedicated To HIV Medicine Two promising young physicians have been awarded this year’s Minority...

Related posts brought to you by Yet Another Related Posts Plugin.

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.

| Copyright 2009 |
pharmacy reviews no prescription online pharmacy buy pain killers xanax online online drugs online phentermine